scPharmaceuticals Inc. (SCPH)

Market Cap	304.83M +15.8%
Revenue (ttm)	49.97M +107.8%
Net Income	-91.72M
EPS	-1.77
Shares Out	53.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,898,632
Open	5.68
Previous Close	5.67
Day's Range	5.65 - 5.71
52-Week Range	1.94 - 6.28
Beta	0.30
Analysts	Buy
Price Target	12.00 (+111.64%)
Earnings Date	Nov 12, 2025

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company’s lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 17, 2017
• Employees: 164
• Stock Exchange: NASDAQ
• Ticker Symbol: SCPH
• Website: https://www.scpharmaceuticals.com

Financial Performance

In 2024, scPharmaceuticals's revenue was $36.33 million, an increase of 167.28% compared to the previous year's $13.59 million. Losses were -$85.15 million, 55.4% more than in 2023.

Analyst Summary

According to 3 analysts, the average rating for SCPH stock is "Buy." The 12-month stock price target is $12.0, which is an increase of 111.64% from the latest price.

Price Target

$12.0

(111.64% upside)

Analyst Consensus: Buy